コンテンツへスキップ
Merck
  • Endometrial carcinoma remaining after term pregnancy following conservative treatment with medroxyprogesterone acetate.

Endometrial carcinoma remaining after term pregnancy following conservative treatment with medroxyprogesterone acetate.

Gynecologic oncology (2000-09-28)
J Mitsushita, T Toki, K Kato, S Fujii, I Konishi
要旨

Successful pregnancies after conservative progestin treatment to young women with endometrial carcinoma have recently been reported. However, it is not known for certain whether the lesion is completely eradicated in such patients. We present a case of residual endometrial carcinoma after term pregnancy which had been treated conservatively before the pregnancy began. A 28-year-old woman with endometrial carcinoma received conservative treatment with high-dose medroxyprogesterone acetate (MPA) and then conceived. After delivery at term, atypical cells were found in the endometrial curettage specimen. A hysterectomy was performed 6 months after delivery and revealed the presence of a small focus of intramucosal, grade 1, endometrioid-type adenocarcinoma. Immunohistochemically, the tumor cells were positive for estrogen and progesterone receptors. We concluded that while MPA treatment had been effective, it had not completely eradicated the carcinomatous lesion, which remained during and after the term pregnancy.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
メドロキシプロゲステロン17-アセタート, ≥97% (HPLC)
USP
メドロキシプロゲステロン17-アセタート, United States Pharmacopeia (USP) Reference Standard
Supelco
メドロキシプロゲステロン17-アセタート, VETRANAL®, analytical standard
メドロキシプロゲステロン17-アセタート, European Pharmacopoeia (EP) Reference Standard
メドロキシプロゲステロン17-アセタート, European Pharmacopoeia (EP) Reference Standard